Other equities analysts have also issued reports about the company. Zacks Investment Research lowered Crispr Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, September 30th. Goldman Sachs Group lifted their target price on Crispr Therapeutics from $52.00 to $75.00 and gave the stock a “neutral” rating in a report on Tuesday, November 19th. Chardan Capital reiterated a “buy” rating and issued a $72.50 target price on shares of Crispr Therapeutics in a report on Monday, November 18th. Needham & Company LLC reiterated a “buy” rating and issued a $84.00 target price on shares of Crispr Therapeutics in a report on Monday, December 23rd. Finally, Wells Fargo & Co reiterated a “buy” rating on shares of Crispr Therapeutics in a report on Friday, December 6th. Three analysts have rated the stock with a sell rating, two have given a hold rating and twelve have given a buy rating to the company’s stock. Crispr Therapeutics has an average rating of “Buy” and an average target price of $71.38.
Shares of CRSP traded down $1.30 during trading hours on Wednesday, hitting $58.33. The company had a trading volume of 1,116,434 shares, compared to its average volume of 1,000,783. The business has a fifty day moving average of $65.14 and a 200-day moving average of $52.14. The firm has a market cap of $3.29 billion, a price-to-earnings ratio of -126.80 and a beta of 3.20. The company has a quick ratio of 8.32, a current ratio of 8.32 and a debt-to-equity ratio of 0.06. Crispr Therapeutics has a 12 month low of $29.34 and a 12 month high of $74.00.
Crispr Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings results on Monday, October 28th. The company reported $2.40 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.95) by $3.35. Crispr Therapeutics had a negative net margin of 5.30% and a negative return on equity of 2.60%. The business had revenue of $211.93 million for the quarter, compared to analyst estimates of $6.32 million. On average, equities analysts expect that Crispr Therapeutics will post 0.65 EPS for the current fiscal year.
In other Crispr Therapeutics news, Director Pablo J. Cagnoni sold 7,500 shares of the business’s stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $55.00, for a total value of $412,500.00. Following the transaction, the director now owns 7,500 shares of the company’s stock, valued at $412,500. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, President Rodger Novak sold 33,618 shares of the business’s stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total value of $2,353,260.00. Following the completion of the transaction, the president now directly owns 33,618 shares in the company, valued at approximately $2,353,260. The disclosure for this sale can be found here. Insiders have sold 56,118 shares of company stock valued at $3,620,760 in the last quarter. 21.40% of the stock is currently owned by corporate insiders.
A number of hedge funds have recently bought and sold shares of CRSP. Nikko Asset Management Americas Inc. lifted its position in shares of Crispr Therapeutics by 48.4% during the 3rd quarter. Nikko Asset Management Americas Inc. now owns 2,777,414 shares of the company’s stock valued at $113,846,000 after buying an additional 906,006 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in Crispr Therapeutics by 19.6% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 738,869 shares of the company’s stock worth $34,801,000 after purchasing an additional 121,176 shares in the last quarter. Wells Fargo & Company MN lifted its holdings in Crispr Therapeutics by 23.9% during the 2nd quarter. Wells Fargo & Company MN now owns 603,905 shares of the company’s stock worth $28,443,000 after purchasing an additional 116,540 shares in the last quarter. Orbimed Advisors LLC purchased a new stake in Crispr Therapeutics during the 3rd quarter worth about $21,167,000. Finally, Morgan Stanley lifted its holdings in Crispr Therapeutics by 6.1% during the 2nd quarter. Morgan Stanley now owns 284,984 shares of the company’s stock worth $13,423,000 after purchasing an additional 16,361 shares in the last quarter. 49.82% of the stock is currently owned by institutional investors and hedge funds.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Read More: What does the Dogs of the Dow mean?
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.